In late November, Vivus launched its Get Started! Program , which gives potential users of its weight management medication Qsymia a chance to try the drug free for two...
Diabetes Drug News
Diabetes Drugs are responsible for helping to decrease blood sugar levels so that you can try to stay in a healthier range and help avoid serious complications.
Metformin Insulin SGLT-2 GLP-1 DPP-4 Combo drugs Sulfonylureas TZDs
37 readers recommended
On February 8, Novo Nordisk received an FDA complete response letter (CRL) for Tresiba (insulin degludec) and Ryzodeg (insulin degludec/aspart). Tresiba is Novo Nordisk’...
71 readers recommended
By Hannah Deming Lately, the use of basal insulins (such as Lantus and Levemir) in combination with GLP-1 agonists (such as Byetta , Victoza , and Bydureon ) has been...
31 readers recommended
In December, Novo Nordisk announced that it will advance FIAsp, an ultra-rapid-acting version of Novolog (insulin aspart), directly into phase 3 trials in late 2013 (the...
54 readers recommended
In January, the FDA announced the approval of three of Takeda’s new once-daily DPP-4 inhibitor pills for type 2 diabetes. DPP-4 inhibitors have been the best-selling...
42 readers recommended
As noted in new now next in diaTribe #37, Novo Nordisk announced in October 2011 that it had submitted its two new “next-generation” insulin products for approval in the...
31 readers recommended
On November 28, CeQur announced that it had received CE Mark approval for its PaQ Insulin Delivery Device , allowing the product to be sold in Europe. The Swiss-based...
50 readers recommended
On February 1, the European Commission announced that it had approved Sanofi and Zealand Pharma’s GLP-1 agonist Lyxumia (lixisenatide) for type 2 diabetes. The drug is a...
36 readers recommended
A candid interview with diaTribe advisory board member Dr. Anne Peters touches on the newest drugs and devices, curing type 1, and addressing obesity.
43 readers recommended
This month, in a surprise move, Vivus announced that its weight management medication Qsymia is now available via mail order through Walmart. This is an addition to the...
24 readers recommended
Two well-known endocrinologists debated the merits of inhaled insulin in the February edition of Diabetes Care.
76 readers recommended
A study in the Journal of the American Medical Association ( JAMA ) found that patients with type 2 diabetes who had been taking the GLP-1 agonists Bydureon (exenatide...
38 readers recommended
On September 17, Vivus announced that its obesity medication Qsymia (formerly Qnexa) is now available on the US market – this happened at least several weeks earlier...
96 readers recommended
Why did Qnexa become Qsymia? diaTribe investigates the thinking behind drug names… and why they’re vital to patient safety.
31 readers recommended
Kelly reflects on some changes here at diaTribe and in the world of diabetes and obesity.
37 readers recommended
In March 2013, Novo Nordisk launched Tresiba (insulin degludec) , its new once-daily basal insulin for type 1 and type 2 diabetes, in the UK and Denmark. Tresiba will be...
65 readers recommended
On August 17, the FDA approved Mylan’s new generic versions of Actos (pioglitazone), a once-daily oral tablet for the treatment of type 2 diabetes originally sold by...
36 readers recommended
Kelly on a heated day at the FDA and why a new drug class could bring diabetes patients, doctors, and educators closer to personalized therapy.
40 readers recommended
On June 27, the FDA approved Arena Pharmaceutical’s weight-loss drug Belviq (lorcaserin), the first weight-loss drug to be approved in the US in 13 years. Belviq is...
37 readers recommended
On March 1, Vivus started its Save Now! program, which sets a discounted price of $75 for one 30-day supply of the company’s weight management medication Qsymia (7.5 mg...